Skip to content
value.today

Pfizer Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, -14.8% a year, held within -10% to 25% (statements).

%

US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt less cash at the end of FY2025 (statements); negative means more cash than debt.

What today's price assumes

A market value of $170.7 B means free cash flow growing 13.2% a year for 10 years, then 2.5% for ever, at a 10.15% discount rate.

Revenue grew -14.8% a year over the last three years.

Cash-flow value of the shares
$-15.9 B
-109% against the market value
Value of the whole business
$44.6 B
before net debt
Value from after year 10
31%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →-15%-12.5%-10%-7.5%-5%
8.15%-112%-108%-103%-96%-88%
9.15%-115%-111%-106%-101%-94%
10.15%-116%-113%-109%-105%-99%
11.15%-118%-115%-111%-107%-102%
12.15%-119%-116%-113%-110%-105%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

P/EP/E of Pharmaceutical: $145.5 B to $408.0 B, median $298.5 BPrice to salesPrice to sales of Pharmaceutical: $95.7 B to $419.3 B, median $216.5 BPrice to bookPrice to book of Pharmaceutical: $184.2 B to $717.8 B, median $351.1 B$0 M$193.8 B$387.6 B$581.4 B$775.2 BMarket value $170.7 B

Your own DCF model

A full discounted-cash-flow model of Pfizer Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Pharmaceutical

Multiples of its companies with a market value at most 60 days old, times Pfizer Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Pfizer Inc.Applied toValue (25th to 75th)Companies
P/E18.7× / 38.4× / 52.5×42.3×net income $7.8 B$145.5 B to $408.0 B53
Price to sales1.5× / 3.5× / 6.7×2.7×revenue $62.6 B$95.7 B to $419.3 B68
Price to book2.1× / 4.1× / 8.3×2.0×book equity $86.5 B$184.2 B to $717.8 B62

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Pfizer Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

39.4×

Now above its median of 18.1×, in the top quarter of its range; range 5.3× to 39.4× over 30 months.

0×10×20×30×39×2020202120222023202420252026P/E 39×Median 18×

Price to sales

2.7×

Now above its median of 2.3×, in the top quarter of its range; range 1.7× to 7.5× over 30 months.

0×2×4×6×8×2020202120222023202420252026Price to sales 3×Median 2×

Price to book

2.0×

Now above its median of 1.7×, in the top quarter of its range; range 1.5× to 5.0× over 30 months.

0×1×2×4×5×2020202120222023202420252026Price to book 2×Median 2×

as of Oct 30, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 30, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$62.6 B$7.8 B$11.7 B$2.6 B$9.1 B$60.5 BSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$63.6 B$8.0 B$12.7 B$2.9 B$9.8 B$56.4 BSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$59.6 B$2.1 B$8.7 B$3.9 B$4.8 B$58.7 BSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$101.2 B$31.4 B$29.3 B$3.2 B$26.0 B$32.5 BSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$81.3 B$22.0 B$32.6 B$2.7 B$29.9 B$34.3 BSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$41.7 B$9.2 B$14.4 B$2.2 B$12.2 B$2.2 BSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $170.7 B on Oct 30, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.